Sunshine Earth Labs Ltd. is legally authorized to research the medicinal uses of restricted substances, and traditional whole plants, as well as the benefits of their pharmaceutical extracts. photo credit: @sunshinelabs
VICTORIA – Sunshine Earth Labs Ltd., a biosciences company that aims to provide harm reduction products to the global market, announced it has entered into a supply agreement with Optimi Health Corp., a leading end-to-end drug researcher and formulator licensed by Health Canada.
Under terms of the agreement, Optimi will supply GMP quality-controlled Full Spectrum Active Pharmaceutical Ingredient (API) and encapsulated psilocybin product, and encapsulated MDMA from Optimi’s 10,000 sq ft, state-of-the-art facility in Princeton, BC.
“Our partnership with Optimi solidifies our commitment to delivering a safe and secure supply of controlled substances globally. Together, we are poised to create a robust pipeline for delivering high-quality psychedelics to the current accessible international market, setting new standards for innovation and reliability,” commented Donovan Edwards, Sunshine’s CEO.
“Our alignment with Sunshine Labs opens opportunities to harness our collective contacts and connections, addressing the global demand for GMP drug substances for research purposes on a meaningful scale,” added Optimi’s CEO, Bill Ciprick.
Both companies are licensed by Health Canada and dedicated to maintaining the highest level of GMP drug production, as mandated by Health Canada under the Controlled Drugs and Substances Act (CSDA) and Part C, Division 2 of the Food and Drug Regulations.
SOURCE Sunshine Earth Labs Ltd.
